Efmirenpase alfa

依米恩酶α

Report date: 2026/04/16 20:00:17

Base Information

Drug NameEfmirenpase alfa
Drug Alias NameINZ-701rhENPP1-FcBMN-401
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Protein drugs > Enzyme
Mechanisms of ActionEctonucleotide Pyrophosphatase/Phosphodiesterase 1 replacements
TargetsEctonucleotide Pyrophosphatase/Phosphodiesterase 1
Therapy Area/IndicationsVascular CalcificationCalciphylaxisPseudoxanthoma Elasticum +[7
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSaudi Arabia +[13
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesInozyme Pharma
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsVascular CalcificationCalciphylaxisPseudoxanthoma Elasticum +[7
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A